School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Celularity Inc CELU

Healthcare · Biotechnology

$1.56last close 2026-10-09 · market cap $50.62M · delayed data

Trailing returns

1M+8.33%
3M+108.56%
6M+14.71%
1Y-26.76%
5Y-97.82%

Basis: Adjusted daily closes.

What it does

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease.

Open CELU in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies